| 0 (0%) | 11-30 07:29 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 12.32 | 1-year : | 14.39 |
| Resists | First : | 10.55 | Second : | 12.32 |
| Pivot price | 10.52  |
|||
| Supports | First : | 10.48 | Second : | 10.43 |
| MAs | MA(5) : | 10.52 |
MA(20) : | 10.52 |
| MA(100) : | 10.47 |
MA(250) : | 10.31 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 62.2 |
D(3) : | 66.6 |
| RSI | RSI(14): 48.6 |
|||
| 52-week | High : | 10.69 | Low : | 10.01 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ LPAA ] has closed above bottom band by 38.9%. Bollinger Bands are 8.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 10.56 - 10.61 | 10.61 - 10.67 |
| Low: | 10.38 - 10.44 | 10.44 - 10.51 |
| Close: | 10.41 - 10.51 | 10.51 - 10.61 |
Thu, 20 Nov 2025
Minovia Therapeutics (LPAA) showcases MDS mitochondrial data and SPAC deal targeting 2026 - Stock Titan
Thu, 06 Nov 2025
Launch One Acquisition Corp. $LPAA Holdings Raised by Wealthspring Capital LLC - MarketBeat
Sat, 01 Nov 2025
Wolverine Asset Management LLC Trims Holdings in Launch One Acquisition Corp. $LPAA - MarketBeat
Wed, 15 Oct 2025
FDA Orphan Drug Designation for MNV-201: Minovia Therapeutics gains ODD; Launch One business combo late 2025 - Stock Titan
Fri, 27 Jun 2025
Launch One Acquisition Corp (NASDAQ:LPAA) Nasdaq Composite - Kalkine Media
Wed, 25 Jun 2025
Breakthrough Mitochondrial Company With FDA Fast-Track Status Going Public in $180M SPAC Deal - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 23 (M) |
| Shares Float | 16 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 103.1 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 4 (K) |
| EPS | 0.28 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.35 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -1 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 36.27 |
| PEG Ratio | 0 |
| Price to Book value | -30.06 |
| Price to Sales | 0 |
| Price to Cash Flow | -210.41 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|